【上交所IPO】北芯生命今起招股 1月26日申购

Core Viewpoint - Beixin Life is planning to publicly issue 57 million shares, all of which are new shares, resulting in a total share capital of 41.7 million shares after issuance [1] Company Overview - Beixin Life focuses on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, aiming to revolutionize solutions in this field [2] - The company's core products include the intravascular ultrasound (IVUS) diagnostic system and the fractional flow reserve (FFR) measurement system, both of which are the first domestically developed products approved by the National Medical Products Administration (NMPA) in China [2][3] - Beixin Life is the first domestic medical device company to offer a combination of FFR and IVUS products, filling a gap in the domestic market and reducing reliance on imported products [2] Product Development - Since its establishment, the company has launched 11 products and has 6 products under development, covering five categories: IVUS systems, FFR systems, vascular access products, shockwave balloon therapy systems, and electrophysiological solutions [3] - The IVUS system is recognized for its high-definition, high-speed, and intelligent features, and is included in the National Key R&D Program for digital diagnostic equipment [3] Financial Data - As of June 30, 2025, the total assets amounted to 838.54 million yuan, with a net profit of 45.51 million yuan, marking a significant improvement from previous years [8] - The company reported a revenue of 258.86 million yuan for the first half of 2025, compared to 186.98 million yuan in 2023 [8] Market Position - Beixin Life specializes in precise cardiovascular disease diagnosis solutions, competing with major companies like Boston Scientific, Abbott, Philips, and Lepu Medical in the IVUS and FFR segments [9] - The company has achieved a leading market share in the domestic market for its core products, significantly reducing the dependency on imports [9][10] - Beixin Life's innovative capabilities and management team position it well for growth in the high-end active interventional diagnosis and treatment market, where domestic competitors have yet to make significant breakthroughs [10]